ClinicalTrials.gov
ClinicalTrials.gov Menu

Economic Evaluation of Heart Failure Management in Colombian Clinics (EconoHeart)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01084564
Recruitment Status : Completed
First Posted : March 10, 2010
Last Update Posted : March 10, 2010
Sponsor:
Information provided by:
AstraZeneca

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Condition or disease
Heart Failure Asthma

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Economic Evaluation of Heart Failure Management in Colombian Clinics
Study Start Date : January 2008
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1
moderate to severe uncontrolled asthma


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia [ Time Frame: 12 months ]
  2. Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Moderate to severe uncontrolled asthma.
Criteria

Inclusion Criteria:

  • Asthma moderate to severe.
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01084564


Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Rodolfo Dennis, M.D. Pontificia Universidad Javeriana
Principal Investigator: MARÍA XIMENA ROJAS, M.D. Pontificia Universidad Javeriana
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01084564     History of Changes
Other Study ID Numbers: NIS-CCO-ATA-2007/1
First Posted: March 10, 2010    Key Record Dates
Last Update Posted: March 10, 2010
Last Verified: March 2010

Keywords provided by AstraZeneca:
Cost-effectiveness analysis
Colombia

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases